

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

---

UCB, INC., UCB MANUFACTURING  
IRELAND LIMITED, UCB PHARMA  
GMBH, and LTS LOHMANN THERAPIE-  
SYSTEME AG,

Plaintiffs,

v.

WATSON LABORATORIES, INC. and  
ACTAVIS LABORATORIES UT, INC.,

Defendants.

---

C.A. No. 14-1083-LPS-SRF

**ORDER**

At Wilmington this **14th** day of **November, 2017**:


For the reasons set forth in the Memorandum Opinion issued this date,

**IT IS HEREBY ORDERED** that:

1. UCB has proven that Actavis' ANDA product infringes claims 1, 5, 7, 14, and 15 of the '434 patent.
2. Actavis has failed to prove that claims 1, 5, 7, 14, and 15 of the '434 are invalid due to anticipation and/or obviousness.
3. Actavis has failed to prove that claims 1-3 of the '414 are invalid for derivation or inherent anticipation.
4. Actavis has proven that claims 1-3 of the '414 are invalid under § 102(a).
5. The parties shall meet and confer and submit, no later than **November 17**, a proposed order consistent with the Memorandum Opinion, to enter final judgment (a) **FOR** Plaintiffs and **AGAINST** Defendants with respect to the asserted claims of the '434 patent and

(b) **FOR** Defendants and **AGAINST** Plaintiffs with respect to the asserted claims of the '414 patent. By the same date, the parties shall submit a joint status report, providing their position(s) as to whether any further proceedings are required.

6. As the Opinion has been issued under seal, the parties shall meet and confer and shall, no later than **November 17**, submit a proposed redacted version. Thereafter, the Court will issue a publicly-available version.

A handwritten signature in black ink, appearing to read "L. P. Stark", written over a horizontal line.

HON. LEONARD P. STARK  
UNITED STATES DISTRICT COURT